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I epartllll'llt of Che<{ alld 1I1t~:nl<)lI< I )ISl'.bn ,lIld 'Lkp. ITlllelll 01" '!lIuea! MKroblol()~, 1-10 riLl! Heekeslmm, affil Frell'
Ul1lVermar Berhll, C;enllJny
LOII!':-.Ktllllot n:l'll.Iln'pnnm are char.rnenzl'd by ,Ill elllllln. [ton
1r.III=-hfe I)f ."-4 III UI) alld lon!\l'r: tl)l' \lilly ,1V:llbhle cerha[o-
'I'0nm utTl'nll~ ,"elr h:llI:"lJve~ an: CUITl'I1t1y ccfll;aXOIIl' and
rdutl't.m. BOlh alltihlOtlCS, and C~pl'cl:dly cel"Olaxolle, h, ve a
lIucrobll1lo",~cal SPl'ctrulll U1at covers the k';ldillg patho!:ells
rlospoll>lblc for lower resplr.rrory tr.rct IIlt~'(1I0l1\ (L11..1'1) hke
Sln'/JlII(llm!> 1'IIi'III11/lIl11W, Htlt'''llll'll/11I "!f1""IIZtll', il"t"m",dit, (mar·
rlllll;, KI..b5;I'I/(/ srI'.. Pm/I'll ,1'1'.. etc.; hm ever, PsclUlml/Olil1S
"rrll,li;I/(lJII, ..j,lll('I<II~l"'I" spp. ,nJ EJlll'mllll(la PI" arc u,u,111y
rl~l",lIIt to Ihese .1I1oblOtl s. COl15lder.rhlc IIlfOnll,101)n 011 the
ph:lrIlL"lCodYII:lnllcs of 13-l:rct,um lu. accul1lulaled in Ihe paM 2t I
years III, Thl're IS a wealth of eVidence to support the COllCq1t
tiLU the pnllClp:ll JeWrIlUII:lOr ofducacy uf[3-laet:um is the time
ahove the MIl: (I Ml) - the rulle tor whl ·Ir drill; level, at
the ~l(e of IlllcWOIl excel'd rhe MIC, Extrapolations from the
lleutropcl1I' :lI1im,tl d:ll.; suggl'Sr Ihal rn the setnng of profound
nClI[r0l'elUa, perllcillin and ccphalosp )rin kvcls need to exceed
Ihe M Ie Inr ')(YY..-I oo')!" ofmt' do mg illu:rv:ll !i>r eUie. cy ag:lin'l
Gr:IIIl-lleg,ltIve bactIL and streptocoCCI, but only for 5ffYo-60'Yr. of
the dO\lIl~ IIltl'rval for ducal' a~lI1s1 staph 10'0 CI, bl'cause of
Ihe pO~hll1t1lll111Ceffecl [21. Ua renost tiC dnlg levels may he all
tiLll i, required 111 Ihe n n-lleUITClpCllic hml, 1Il \ hlch caSl' levels
Ileed to exc;:...d rhe MI : for mly al'proxlillalely 2IY)(" 25')1,.-30%
and 25%~(J%of the clo.Sllll:\ mtervallilr c, rbapenelm, pelllClUin$
and n:pha.losponns. rC"ipectivcly III, Amibll tiCS like ce otetan
and .::ciOl xone :lfl' characrerlzed hy high protelll bllldrng In
saUlIl ('.111% ,lIId 1Il0rc). wlueh ha.s lO be tak 'II Illto conslderatH)1l
whell calculatlllg the r\ pccnve ph,In11a 'okll1ctlc Ild phanlla-
COdYII~I1lIC pa r:1I lll'I\'l" , HC""eva, I;\kmg togl·ther phaml.lcokJ-
IlClK and phanna 'od>'nallllc paralllcI 'rs, cclbiaxonl' could be
,,.!lllll1lstcred III a ,10~lge of 1-2 g ollce daily and tillS d 5a",'C ha,
proven Its high dIi:lc 111 1l1.11ly in,ections.
II1ce ceforelan IS mostly used III . lIq;lc. I pmph laxls and
eroble as wclJ as anacroblc mixed mlcctlollS, rillS paper WIll
mainly foclI, 011 the position f cefmaxone 111 LR1'1.
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III e,lrl: rnal, l:cfin.xone. u uaUv Jt .1 Jo ge of I-::! g onel'
d,lIly, has h,'en compared wllh cdaman.lole, (cfotJXIIlll',
amoX!cilllll "lone or (ul1lbancJ \ rh tobr,lIl1y'lll .1llJ wltl1
('L·folllCld. In most 'tmhes cefrn:Lxone was 'Illubr In ctl10c to
the cOlllparatlVe ttl'atlllcm n:gunen, With no statlStlcall,
'lgml1l'anr dlflcr,"nces berwl.'en lrearlllenr groups able I).
Ncar! aU palll.'nrs rn:areJ Wl·rl.' dlagno l'd as havlllg pnelllllO-
nla, With :I dillcreno,ltIon berween aOllc pneulllolll,l and .1ClJ(C
l''x,1ccrb,arion ( f 'hrollle brolldlltlS, he dctinlton of' :11111<:,11
emc' vaned hel\ eell ~rudll'~, WIth "men,1 bClIlg eontinel! ((l
dlnlCal c'Vldcllce oilly III rhe ~rudle~ of Dmner et .:tl. 13! alld
GrasSl and M,lIl~arorn IRl, whih: requinng conCOmi[3nt
eradiCatiOn of rhe onglllJI cOllllllllmlY acqUIred pathogcn by
lhumg,lrlller anI Gbuser 1-11. An 'overall cure' W.b de,cnbed
by Abbate l'l .11. 151, whl h requlH,d .II appearanCL"i ot'dllucal
and radiogral'llic sIgns and symptotn$ plus erarucatlon of the
..au~atiVt' pathogl'n \\~thollt ub~tlult1on by another rgaru. m.
In a large mulucenter mal, 6')(, paoel1l:\ (.370 rnCUI110IllJ. 30 I
ex.lccrbaoon of chromc brondutlS, 2S ,urays) were ttl:: tA:d WIth
cdm.1xolle 1-2 g Ultravellollsly and IIIcrallluscularly for 20 da~.
TherapeUtic SlleCl"iS was acluevcd In 9(,% ( 'olllrleu,' nlre 111 60%),
wilh eradication ofbactcnalpalhogcns occumng In II "fill.
Two ex cllc'nr fandonu2cd double bhml ~t\ldie~ companng
ccftnaxone With cd taXlllle tor senous bacten:u mfectiom
were paf rllleJ in C311ada [91 :md In the USA 110) In the I:lre
II)Htls. 111 rhe anadlall sUldy a roral of 325 panents were
entered IIltO the rudy over 3. 23-l11onlh pcnoJ. All ascs \Vi.'rC
.lV, liable r. r r.)XI It)' ,m Iy IS, hur R-I (_5,R%) , crl' lIlehgJbll'
ti)f effieat·y lIaly,,~, Thc JeOlograplll<: Jnd prognostic
eh, 1';1 ·tertSlIcs of the 2-11 available ca5l"~ In: shown 111 Table
2. Fifty-five of 12J l'diri, xone p lIel1ts 3.l1d 52 of II
cfOI,lX.lllle-lreated I'anellll h, d ,1 LR I. Patients Wl're ttl'aled
with l'llher intravenous 2 ~ ccli:naxone every 2-1 Il or dati)'
llluJt.lple-dose til crap WHh CefOlaXlllle (2 g every 6 h). Thc
cliluca! cmac)' I" thc srudy drug., are depi red In able 3. Till'
an.lly'l f dlllle,11 alld haetcriologleal re'ponw Jml advel'e
drug react:l 1nl showed no slgnifiolll d,tlcren e~ hcrween rhe
regllllcllS. In rhe 32S CaR., aVdilablc tor roX! Iry, I 5 Jelve e
l"Vent~ rd. tl'Ci to dnlg lise were recorded, 60 In the Celln<L'l:One
i,'TOllp and 75 In the ceforaximc group ahle -I), necc~lt:atlng
di.\ ollonuauon 0 antibactenal therap' 111 fivc and seven
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Table 1 Summary of resulls oblOined In studies comparing Ihe clinical efficacy of cef1riB~one wllh other antlbaclerial regimens In pallen's with
lower resplralOry ,nfeCllons
Relerence No. 01 patients Dosage regimen Success ('Yo cure)
(5) 172 CRO 1-2g od 73/74 •
CTX 2g bid 63/47
[4J 47 CRO 2g od 91
39 AMX 19 qid 69
[3} 16 CRO 19 bid 94
14 CTX 1 5g qld 76
[6) 121 CRO 19 od 95
CNC 19 od 93
(7) 20 CRO 50 mg/kg od 100
19 AMX 50 mg/kg + TM 5 mg/kg 95
AbbrevlBtlons: CRO. cetlria~ona; CTX. cefola~lme; AMX. amoxyclllln; CNC. celonlcld: TM. lobramycln. 'Acute/chronic Inlecllon
Table 2 Demographic and prognostic characlerlstics of 241 evaluable
cases
Treatment group
Table 4 Adverse drug effeclS in 325 pallents treated Wilh ceftria~one
or cefota~ime
No. (%) of events in
treatment group
'Infuslon SilO complications Included phlabills. locol cellulitis and
burnmg or pain on admlnisllalion Modified Irom (9)
Celtrlaxono Cefotaximo
CharaC1l1ristlc (n = 123) (n-=118)








Concomltanr disease 178 169
Infcolion site
Lung 55 62
Ullnary Irac, 22 20
Skin and soh tissue 20 23
Bone end loint 11 12
Hepatoblliary 2 :3
Bacteremia 13 8
Concomllanl diseas Include cardiovascular. rospuetory. neopla51lc.
cerebrovascular. gastrom,osunal. metabolic. ronal. hepatic and alcohol
or olher drug abuse. The number of concomitant diseases e~ceeds lhe
number of patients treeled because some parients hed more than one
concomitant illness Mod fied from (9).
Adverse eHect
Nephrolo~ICIIY
Nausea with or withoul vomiting
Diarrhoaa
Elevated liver function tests
Alkaline phosphatase

































Table 3 Clinical efficacy of celtri.~ono \1$. cefot8~ime in 241 patients and in 173 patients with definite infections































o to ere number (%) of responses to anlim crobiel therapy. 'Withdrawn from 1he study because of adverse drug reactions. Because thay received
I than 3 day. of treolment. anoly.ls of effie ty was nOI possible. Modified from (9).
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p.1IICII1\. rc'pc<:t1vcl' Thc -Ol1dllSIOn of rhc .1Ulhor.. of thIs
brl-:" ,lUd\, w." Ih.lt ,bll\' 'IIII-:Ic ,lose theLlpy wllh n·tinJxolle
W.I' <:01l1p.1L,hlc \\'Ilh d.llly l11ulnplc d,he thcr.lp. wlrh
<:clut.I'(lIl1e III Ire.1l11l1-: ,enml' h.ll'len.II IIllc<:1I01l'.
III Ihe U') mllly IrOli1 th,' Johll\ Ilopklll\ H"'pil;ll III
1l.lllIlIhlr,·. MI), I X7 p~t1,'Ill' \\','1',' Ill' luded, .111.1 Lrl'. tcd wnh
"lIlwl ,elirt.lXOll'· 21-: OII'e.1 d.l. or 2!( Of<:c!'ll:lXIIII" \IX lillIe,
d.I,I~ -1,.t1 OIlI,I.I?olc \\,," .1 Idcd when .m.l,'roh,<: IIlIC<:tlllll \\'.1'
'lI'p", r,,1 rlll.1l1\' (.-1 r.III'IlI' III rhe <:elrnJXOllc broliP alld 51
p.llICIll' III the <:clOLIXII1IC ~roup 1t,IlI provell Inlccnom.
l'we111'\'-1\\ " 01 (0-1 111 the cl'lin.lxol1e ~1'OliP .lIld IS f 5 I In the
-clOIJ!llllll' ~I'llllp "ere Lit n. The toLli rc,pUll\\' rale was
HI'~" lor cdin.lx"lle .111.1 KlI"'fo tor CdCll.1XIIII, oVl'r.llI. 111 the
IHlIl-lInll.lry tr.u:t InfcClIOII\ rhc\c li~lIrc, were 77% for
<:dinJ:\"l1l' .111.1 7 I'},. lor <:ellll:I)(ll1Ie. The freqllell<:y of
,!I.1IThe.l. rhr IIlbn-phlcblll'. I'TOlhmlllblil prololl~ltIon.
L(.I0I117.1tI011 .111d \uperinfectlon ,hd not ,lIffer b"I\\'e 'n Ire;ll-
I11CIlI ,,'TOUp' The authof'l conclll,kd th.1l 2 g of <:clin~xol1\'
,111l,' .1 .1.1)' W.l\ a' ,,11<: ,lIld dk<:ove ~\ CdtlLl)(tlne 2 g ,'vcry -I h.
.'OIllC r<:n'lH ,tlldl'" Irolll "rad II II .lIld G,nll.lIly 112,131
report... 1011 th .. I-:ood etlic;Ky of I ~ n-t'tnJxon... III the Iherapy
01 "'n,Hl' COI1lI1I11l1lry acqUIred pnCUI1l0llla .1' wcli :" III the
tTl'.llInelll of lIloder:llc to ,,'V,'T'" 11o, conll.II plleUIlIQlll.1,
0111,' 01 Ihl' l' grollp' IIlldeT\corl'd Ihc .1,ldmllll, I co. I
cllC,lI\'cIIC\\ of I g "etinaxolle 11\ llllllp.II1\11I1 \\ Ilh \ecolld-
gCller. tlon .Ind ()liter thirJ-~enerJn 11 ,,·ph,lo\ponn.ll.
Th,' e.·celll'lll dlllical n:sults III <:OlllleClI 11 WIth a broad
.lIltlb.I<:lcn.d 'peurum JS well .1' a !:worable pharn1.l Okllll'rtC
JIIJ ph.IrI11.l(OJYIIJIIU\ dl.lr.I'ten,tlc of ccliTiaxone were .1\0
lhl' 1>.1\1\ f r cl\lenl1~ thl\ ,lIlllbllH!C III (he currellt ~IIlJdllles
I~Jr tre.III1,'m of ho rllJ1I7cd p.me III \ \ Itll "Olllllllll1lry-
.1l''!lIlrcd 1"1ClllllOl1I.1 III til<' USA [1-11 .m'! :\11'01'" [151.
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